Observational studyAnnals of hematology2023

Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients.

A Chistolini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.